Eradication of invasive pneumococcal disease due to the seven-valent pneumococcal conjugate vaccine serotypes in Calgary, Alberta

Pediatric Infectious Disease Journal

Volumn 31, Issue 9, 2012, Pages

  Leal, Jenine ^a   Vanderkooi, Otto G ^a,b,c,d   Church, Deirdre L ^c,d   MacDonald, Judy ^c,e   Tyrrell, Gregory J ^f,g   Kellner, James D ^a,b,c  

^a Department of Pediatrics ^*  (Canada)

^b Department of Microbiology Immunology and Infectious Diseases   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d CALGARY LABORATORY SERVICES   (Canada)

^e ALBERTA HEALTH SERVICES   (Canada)

^f National Centre for Streptococcus   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

Author keywords

7 valent pneumococcal vaccine; Alberta; Canada; epidemiology; invasive pneumococcal disease; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; VITEK 2;

ADOLESCENT; ADULT; AGED; ARTICLE; CANADA; CHILD; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SURVEILLANCE; ERADICATION THERAPY; HUMAN; INFANT; MAJOR CLINICAL STUDY; PNEUMOCOCCAL INFECTION; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SEROTYPE; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALBERTA; CHILD; CHILD, PRESCHOOL; DISEASE ERADICATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PROSPECTIVE STUDIES; STREPTOCOCCUS PNEUMONIAE;

EID: 84865471144     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182624a40     Document Type: Article

References (39)

1. Flasche S, Van Hoek AJ, Sheasby E, et al. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med. 2011;8:e1001017.
2. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4: 144-154.
3. Kellner JD, Scheifele D, Vanderkooi OG, et al. Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with streptococcus pneumoniae in children in Calgary, Canada. Pediatr Infect Dis J. 2008;27:526-532.
4. Gray BM, Converse GM 3rd, Dillon HC Jr. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis. 1980;142:923-933.
5. Grall N, Hurmic O, Al Nakib M, et al. Epidemiology of Streptococcus pneumoniae in France before introduction of the PCV-13 vaccine. Eur J Clin Microbiol Infect Dis. 2011;30:1511-1519.
6. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med. 2010;16:217-225.
7. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet. 2009;374:1543-1556.
8. Bettinger JA, Scheifele DW, Kellner JD, et al. The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine. 2010;28: 2130-2136.
9. Kellner JD, Vanderkooi OG, MacDonald J, et al. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis. 2009;49:205-212.
10. Whitney CG, Farley MM, Hadler J, et al.; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746.
11. Hsu K, Pelton S, Karumuri S, et al.; Massachusetts Department of Public Health Epidemiologists. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr Infect Dis J. 2005;24:17-23.
12. Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113(3 Pt 1):443-449.
13. Lexau CA, Lynfield R, Danila R, et al.; Active Bacterial Core Surveillance Team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294:2043-2051.
14. Pilishvili T, Zell ER, Farley MM, et al. Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use. Pediatrics. 2010;126:e9-17.
15. Dagan R. New insights on pneumococcal disease: what we have learned over the past decade. Vaccine. 2009;27(suppl 3):C3-C5.
16. Prato R, Tafuri S, Fortunato F, et al. Why it is still important that countries know the burden of pneumococcal disease. Hum Vaccin. 2010;6:918-921.
17. Kellner JD, Church DL, MacDonald J, et al. Progress in the prevention of pneumococcal infection. CMAJ. 2005;173:1149-1151.
18. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests. 9th ed. Approved standard M02-09. Wayne, PA: Clinical and Laboratory Standards Institutes; 2006.
19. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 7th ed. Approved standard M7-A7. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
20. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 16th Informational Supplement, M100-S16. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
21. Vanderkooi O, Church D, MacDonald J, et al. Community-Based Outbreaks in Vulnerable Populations of Invasive Infections caused by Streptococcus pneumoniae Serotypes 5 and 8 in Calgary, Canada. PLoS ONE. 2011;6:e28547.
22. Pilishvili T, Lexau C, Farley MM, et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32-41.
23. Grijalva CG, Pelton SI. A second-generation pneumococcal conjugate vaccine for prevention of pneumococcal diseases in children. Curr Opin Pediatr. 2011;23:98-104.
24. Beall BW, Gertz RE, Hulkower RL, et al. Shifting genetic structure of invasive serotype 19A pneumococci in the United States. J Infect Dis. 2011;203:1360-1368.
25. Pai R, Moore MR, Pilishvili T, et al.; Active Bacterial Core Surveillance Team. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis. 2005; 192:1988-1995.
26. Harboe ZB, Benfield TL, Valentiner-Branth P, et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis. 2010;50:329-337.
27. Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21:810-815.
28. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunization with pneumococcal conjugate vaccine in the USA time series analysis. Lancet. 2007;369:1179-1186.
29. Simonsen L, Taylor RJ, Young-Xu Y, et al. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2011;2:e00309-e00310.
30. Lin SH, Lai CC, Tan CK, et al. Outcomes of hospitalized patients with bacteraemic and non-bacteraemic community-acquired pneumonia caused by Streptococcus pneumoniae. Epidemiol Infect. 2011;139:1307-1316.
31. Hendrickson DJ, Blumberg DA, Joad JP, et al. Five-fold increase in pediatric parapneumonic empyema since introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2008;27:1030-1032.
32. Byington CL, Korgenski K, Daly J, et al. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr Infect Dis J. 2006;25:250-254.
33. Levy C, Varon E, Bingen E, et al.; Bacterial Meningitis Study Group. PneumococcaL meningitis in french children before and after the introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2011;30:168-170.
34. Alexandre C, Dubos F, Courouble C, et al.; Hospital Network for Evaluating the Management of Common Childhood Diseases. Rebound in the incidence of pneumococcal meningitis in northern France: effect of serotype replacement. Acta Paediatr. 2010;99:1686-1690.
35. Dubos F, Marechal I, Husson MO, et al.; Hospital Network for Evaluating the Management of Common Childhood Diseases. Decline in pneumococcal meningitis after the introduction of the heptavalent-pneumococcal conjugate vaccine in northern France. Arch Dis Child. 2007;92:1009-1012.
36. Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360:244-256.
37. Bingen E, Levy C, Varon E, et al.; Bacterial Meningitis Study Group. Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation. Eur J Clin Microbiol Infect Dis. 2008;27:191-199.
38. Peltola V. Pneumococcal meningitis still with us in the era of conjugate vaccines. Acta Paediatr. 2010;99:1600-1601.
39. Skinner JM, Indrawati L, Cannon J, et al. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. Vaccine. 2011;29:8870-8876.